• Loading stock data…

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

[#item_full_content]

Print Friendly, PDF & Email
Spread the word